Figure 5.
XAV939 and IWR1-endo decrease Wnt activity in CASCs. Representative Western blots (left panels) and subsequent quantification (right panels) of both total and active β-catenin after treatment with small-molecule Wnt inhibitors in (A) CASCs and (B) SW480 cells. Data bars represent medians ± IQR (n = 6 individual patient CASC cultures/condition); * p < 0.05, ** p < 0.01 compared to respective control.